Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4782675 | 0.86 | TBXAS1 (0.39) | TBXAS1CYP3A4CYP2D6PKMCYP1A2 | |
| SCHEMBL2361037 | 0.71 | HTT (0.54) | CYP3A4CYP2D6PKMCYP1A2CYP2C9 | |
| SCHEMBL14282208 | 0.69 | RAB9A (0.53) | CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL10824672 | 0.69 | KMT2A (0.41) | CYP3A4PKMCYP1A2CYP2C19 | |
| SCHEMBL2323909 | 0.69 | GAA (0.41) | PKM | |
| SCHEMBL14282209 | 0.68 | NOTUM (0.54) | CYP3A4CYP1A2 | |
| SCHEMBL14221370 | 0.68 | ALDH1A1 (0.56) | CYP3A4CYP2D6CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL14282212 | 0.68 | GAA (0.48) | CYP3A4CYP2D6CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL14282211 | 0.67 | NPBWR1 (0.46) | CYP3A4CYP1A2 | |
| SCHEMBL14282213 | 0.67 | CYP17A1 (0.56) | CYP3A4PKMCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1497269-B1 | SUBSTITUTED 2-PHENYL-3(2H)-PYRIDAZINONES | BAYER HEALTHCARE AG (DE) | 2008-04-23 | — | — | EP | disclosed |
| US-7320977-B2 | Fibrotic disorders; disorders characterized by harmful buildup of collagen and/or by excessive lysyl oxidase enzymatic activity | BAYER HEALTHCARE AG (DE) | 2008-01-22 | — | — | US | disclosed |
| US-20060004015-A1 | Substituted 2-phenyl-3(2h)-pyridazinones | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-01-05 | — | — | US | disclosed |
| EP-1497269-A1 | SUBSTITUTED 2-PHENYL-3(2H)-PYRIDAZINONES | Bayer HealthCare AG (DE) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003097612-A1 | SUBSTITUTED 2-PHENYL-3(2H)-PYRIDAZINONES | BAYER HEALTHCARE AG (DE) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004015-A1 | Substituted 2-phenyl-3(2h)-pyridazinones | PIR, TPMT, PNPO | TBXAS1 972/4885CYP3A4 246/4885CYP2D6 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.